The association of women’s birth size with risk of molecular breast cancer subtypes: a cohort study

Sandvei, Marie Søfteland; Opdahl, Signe; Valla, Marit; Λάγιου, Παγώνα; Vesterfjell, Ellen Veronika; Rise, Tor Vikan; Overrein, Tina Syvertsen; Skjervold, Anette H.; Engstrøm, Monica Jernberg; Bofin, Anna M.; Vatten, Lars J.

doi:10.1186/s12885-021-08027-9

Cited by 4 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most recent and pioneering large cohort study was conducted in 2021 by Sandvei et al with 22.931 Norwegian women born 1920-1966 ( 16 ). For this study data were collected about perinatal and maternal factors, including the birth weight in order to find a possible relationship with breast cancer risk and for first time the molecular subtype.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, mammotropic hormones, including prolactin, human placental lactogen (hPL) and also Growth Hormone (GH) play an important role in the mechanism of breast malignancy. These hormones in high levels affect the still growing mammary gland of the fetus and increase the number of the mammary gland-specific stem cell leading to elevated risk for breast cancer ( 16 ). In conclusion, a supplementary explanation for this trend could be the fact that high weight at birth is associated with increased mammographic density and earlier start of menstruation, two established risk factors of breast cancer ( 1 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study

Bothou

Zervoudis²,

Tsatsaris

et al. 2021

Mater Sociomed

View full text Add to dashboard Cite

Background: It is a global fact that the birth weight is increasing during the years around the world and for this reason it is very important to be examined as a potential risk factor for breast cancer. According to data from World Health Organization, breast cancer is the second most frequent malignancy across the world, after lung cancer, in Europe including Greece in incidence and mortality for women between the ages 0-85 years old. Objective: The aim of this study was to investigate a possible association between neonatal birth weight of the women and breast cancer risk in Greek women. Although that many studies concluded that birth weight is positively related with breast cancer reinforcing the theory that breast cancer may originate in utero, some studies found no association. Moreover, the results from previous studies are inconsistent maybe due to several factors such as the study design and the number of cases. Methods: This study was a case-control retrospective bicentric study. The case group included 238 women with breast cancer, while the control group included 153 women without breast cancer who consulted in two breast clinics in Greece. In all women, a clinical examination and breast ultrasound were achieved. Moreover, digital bilateral mammography was performed in patients older than 40 years. Results: According to Fisher’s exact analysis, there is a statistically significant relationship between the higher women’s neonatal birth weight and the risk for breast cancer (p<0.001). More specifically in the group of women with breast cancer, 61% of them had more than 3500 grams birth weight, in contrast with 7.8 % in the control group. In our cohort, women who had birth weight more than 3500 grams are more likely to develop breast cancer in their life. Conclusion: Our study trend to show that the increased neonatal birth weight may influence future risk of breast cancer. However, further studies with larger number of participants are needed in order to clarify the role of birth weight as a complementary risk factor of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study

Bothou

Zervoudis²,

Tsatsaris

et al. 2021

Mater Sociomed

View full text Add to dashboard Cite

show abstract

“…Information regarding incident breast cancers was obtained from the Cancer Registry of Norway using national identity numbers to link person data. The breast cancers that occurred among these women have previously been characterized by our group, and they were reclassified into histological grade and molecular subtypes [ 7 , 8 , 37 ]. As part of histological grading [ 38 , 39 ], mitotic counts were registered for all available tumours, and as part of molecular subtyping, Ki-67 positive cells were counted in 500 tumour cells.…”

Section: Methodsmentioning

confidence: 99%

“…All women born at E. C. Dahl’s foundation in Trondheim (in the southern part of Trøndelag) between 1920 and 1966 were followed for breast cancer occurrence from January 1st, 1961, until the date of breast cancer diagnosis, death from other causes, emigration, or December 31st, 2012 [ 42 ]. Of the 23,350 women included, 885 incident breast cancer cases were registered [ 37 ]. Participants were followed until death from breast cancer or any other causes, or until December 31st, 2015.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Long term trends of breast cancer incidence according to proliferation status

Klæstad,

Opdahl,

Raj

et al. 2022

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Long-term breast cancer incidence trends according to proliferation status are poorly described. We studied time-trends in breast cancer incidence, using mitotic count and Ki-67 as markers of proliferation. Methods Among 83,298 Norwegian women followed for breast cancer occurrence 1961–2012, 2995 incident breast cancers were diagnosed. Ki-67 was assessed using immunohistochemistry on tissue microarrays and mitoses were counted on whole sections. We compared incidence rates according to proliferation status among women born 1886–1928 and 1929–1977, estimating age-specific incidence rate ratios. We performed multiple imputations to account for unknown proliferation status. Mean values of Ki-67 and mitotic counts were calculated, according to age and birth year. We performed separate incidence analyses for HER2+ and triple negative breast cancers. Results Among women aged 40–69 years, incidence rates of tumours with low-proliferative activity were higher among those born in 1929 or later, compared to before 1929, according to Ki-67 and mitotic count. Incidence rates of tumours with high-proliferative activity were also higher in women born in 1929 or later compared to before 1929 according to Ki-67, but not according to mitotic count. Mean values of Ki-67 and mitotic count varied according to age and birth year. In subtype-specific analyses we found an increase of high-proliferative HER2+ tumours according to Ki-67 in women born in 1929 or later, compared to before 1929. Conclusions There has been a temporal increase in both low- and high-proliferative breast cancers.

show abstract

Oestrogen receptor low positive breast cancer: associations with prognosis

Skjervold

Valla

Bofin

2023

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Purpose In this study of oestrogen receptor (ER) Low Positive breast cancers (BC) in three large cohorts of BC patients, we assess associations between levels of ER expression and tumour characteristics and prognosis. Methods Cases were stratified into patients unlikely to have received adjuvant therapy according to treatment guidelines at time of diagnosis (before 1995), and those who could have received adjuvant therapy (diagnosed in 1995 or later). ER status was divided into < 1%; ≥ 1 < 10%; ≥ 10%. Results were correlated with time of diagnosis, histopathological grade, proliferation status, and molecular subtypes, using Pearson’s Chi-square test. For prognosis, hazard ratios and cumulative incidence of death from BC were used. Results Of the 1955 tumours, 65 (3.3%) were ER Low Positive (ER ≥ 1 < 10%). Overall, the highest proportion of ER Low Positive tumours was observed among Luminal B (HER2 +) subtype (9.4%) and grade 3 tumours (4.3%). The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Compared to patients diagnosed before 1995, women diagnosed in 1995 or later showed a higher proportion of ER Low Positive BCs, and their tumours were of smaller size, lower grade, and lower proliferative status. There was no significant difference in prognosis compared to those with ER ≥ 10% tumours. Conclusion Women with ER Low Positive tumours diagnosed in a time period when adjuvant therapy was available had tumours of smaller size, lower grade, and lower proliferative status, and similar prognosis to those with ER ≥ 10% compared to women diagnosed earlier.

show abstract

The association of women’s birth size with risk of molecular breast cancer subtypes: a cohort study

Cited by 4 publications

References 28 publications

Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study

Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study

Long term trends of breast cancer incidence according to proliferation status

Oestrogen receptor low positive breast cancer: associations with prognosis

Contact Info

Product

Resources

About